Until today, one of the most dangerous diseases in the field of medicine is leukemia, the etiology and pathogenesis of which has not been fully determined. According to world statistics, leukemia is 13.2% per 100,000 population. Chronic myeloid leukemia, which ranks 3rd among common blood diseases, accounts for 15-20% of all leukemias.

chronic myeloid leukemia, sinusoidal capillaries, Philadelphia chromosome, imatinib, mobilization of hematopoietic cells

Mohammadhossein Hassanshahi, Alireza Hassanshahi, Samira Khabbazi, Yu-Wen Su, Cory J Xian “Bone marrow sinusoidal endothelium as a facilitator/regulator of cell egress from the bone marrow”-2019

American association for cancer research (AACR) publications.

American society of hematology (ASH)- “Blood journals”

Bedi A, Zehnbauer BA, Barber JP, Sharkis SJ, Jones RJ. Inhibition of apoptosis by BCR-ABL in chronic myeloid leukemia. Blood. 1994;83:2038–2044.

Bhatia R, Holtz M, Niu N, Gray R, Snyder DS, Sawyers CL, Arber DA, Slovak ML, Forman SJ. Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment. Blood. 2003;101:4701–4707.

Chu S, Xu H, Shah NP, Snyder DS, Forman SJ, Sawyers CL, Bhatia R. Detection of BCR-ABL kinase mutations in CD34 + cells from chronic myelogenous leukemia patients in complete cytogenetic remission on imatinib mesylate treatment. Blood. 2005;105:2093–2098.

Copland M, Hamilton A, Elrick LJ, Baird JW, Allan EK, Jordanides N, Barow M, Mountford JC, Holyoake TL. Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction. Blood. 2006;107:4532–4539.

Cramer K, Nieborowska-Skorska M, Koptyra M, Slupianek A, Penserga ET, Eaves CJ, Aulitzky W, Skorski T. BCR/ABL and other kinases from chronic myeloproliferative disorders stimulate single-strand annealing, an unfaithful DNA double-strand break repair. Cancer Res. 2008;68:6884–6888.